Download PDF
Horm Metab Res
DOI: 10.1055/a-2281-0911
Original Article: Endocrine Care

Lipid Profile Evolution in Graves’ Disease Treated with Titration Regimen of Anti-Thyroid Drugs Versus Block and Replace Regimen

Ana-Maria Stancu 
1   Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2   Endocrinology IV, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
,
Oana Pop
1   Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
,
Mariana Purice
3   Research Department, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
,
Corin Badiu
1   Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2   Endocrinology IV, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
› Author Affiliations Funding Information European Social Fund Plus — http://dx.doi.org/10.13039/501100004895; POCU/993/6/13/154722
› Further Information
Also available at
    Permissions and Reprints

Abstract

The aim was to compare the lipid profile of patients with GD treated with anti-thyroid drugs (ATDs) using a titration regimen versus a block and replace regimen. This is an 18-month prospective observational study. In this study were included 149 medically treated GD patients, aged+>+18 years. Pregnant women and patients treated with radioactive iodine therapy or partial/total thyroidectomy were excluded. Patients were divided into 2 subgroups: titration (A) and block and replace (B) therapy, according to the ATD regimen used. Thyroid and metabolic profile was measured at baseline and at least one visit during medical treatment. The whole group included 122 (81.87%) females (F) and 27 (18.12%) males (M), ratio F:M=4.5:1. As expected, at the time of diagnosis, thyrotoxic patients were with normal lipid profile. During medical treatment, in patients who achieved euthyroidism, the cholesterol levels increased as follows: in subgroup A: by 52.9 mg/dl (95% CI: 26.4–79.3), p<0.001 for total cholesterol (T-C), by 33.3 mg/dl (95% CI: 10.3–56.3), p=0.007 for low-density lipoprotein cholesterol (LDL-C) and by 11.44 mg/dl (95% CI: 3.08–19.79), p=0.009 for high-density lipoprotein cholesterol (HDL-C); in subgroup B T-C increased by 45.1 mg/dl (95% CI: 22.2–68), p<0.001 and for LDL-C by 33.57 mg/dl (95% CI: 12.72–54.42), p=0.003. No statistically significant increase in triglyceride levels was determined. Medical treatment of hyperthyroidism due to Graves’ disease increased cholesterol levels regardless of the ATD regimen used.

Keywords

hyperthyroidism - cholesterol - block-replace - titration - Graves’ disease


Publication History

Received: 04 December 2023

Accepted after revision: 27 February 2024

Article published online:
02 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Ross DS, Burch HB, Cooper DS. et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421
    CrossrefPubMedGoogle Scholar
  • 2 Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013; 9: 724-734
    CrossrefPubMedGoogle Scholar
  • 3 Sharma M, Modi A, Goyal M. et al. Anti-thyroid antibodies and the gonadotrophins profile (LH/FSH) in euthyroid polycystic ovarian syndrome women. Acta Endocrinol (Buchar) 2022; 18: 79-85
    CrossrefPubMedGoogle Scholar
  • 4 Genc GC, Celik SK, Arpaci D. et al. Granulysin peptide and gene polymorphism in the pathogenesis of Hashimoto thyroiditis. Acta Endocrinol (Buchar) 2022; 18: 288-293
    CrossrefPubMedGoogle Scholar
  • 5 Chen Y, Wu X, Wu R. et al. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism. Sci Rep 2016; 6: 1-7
    CrossrefPubMedGoogle Scholar
  • 6 Abrams JJ, Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981; 22: 323-338
    CrossrefPubMedGoogle Scholar
  • 7 Senese R, Cioffi F, Petito G. et al. Thyroid hormone metabolites and analogues. Endocrine 2019; 66: 105-114
    CrossrefPubMedGoogle Scholar
  • 8 Senese R, Lasala P, Leanza C. et al. New avenues for regulation of lipid metabolism by thyroid hormones and analogs. Front Physiol 2014; 5: 1-7
    CrossrefPubMedGoogle Scholar
  • 9 Bartalena L. Hyperthyroidism due to Graves’ disease – is there an optimal pharmacological treatment regimen?. Eur Endocrinol 2008; 4: 63-65
    PubMedGoogle Scholar
  • 10 Hashizume K, Ichikawa K, Sakurai A. et al. Administration of thyroxine in treated Graves’ disease – effects on the level of 464 antibodies to thyroid stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953
    CrossrefPubMedGoogle Scholar
  • 11 Masiello E, Veronesi G, Gallo D. et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 2018; 41: 1425-1432
    CrossrefPubMedGoogle Scholar
  • 12 Abraham P, Avenell A, Park CM. et al. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 2005; 153: 489-498
    CrossrefPubMedGoogle Scholar
  • 13 Vaidya B, Wright A, Shuttleworth J. et al. Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves’ disease: A retrospective observational study. Clin Endocrinol (Oxf) 2014; 81: 610-613
    CrossrefPubMedGoogle Scholar
  • 14 Duntas LH. Block-and-replace vs. titration antithyroid drug regimen for Graves’ hyperthyroidism: two is not always better than one. J Endocrinol Invest 2021; 44: 1337-1339
    CrossrefPubMedGoogle Scholar
  • 15 Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012; 96: 269-281
    CrossrefPubMedGoogle Scholar
  • 16 Kotwal A, Cortes T, Genere N. et al. Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105: 3683-3694
    CrossrefPubMedGoogle Scholar
  • 17 Sauter G, Weiss M, Hoermann R. Cholesterol 7 alpha-hydroxylase activity in hypothyroidism and 481 hyperthyroidism in humans. Horm Metab Res 1997; 29: 176-179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 O’Brien T, Katz K, Hodge D. et al. The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. Clin Endocrinol (Oxf) 1997; 46: 17-20
    CrossrefPubMedGoogle Scholar
  • 19 Vrca VB, Mayer L, Škreb F. et al. Antioxidant supplementation and serum lipids in patients with Graves’ disease: Effect on LDL-cholesterol. Acta Pharm 2012; 62: 115-122
    CrossrefPubMedGoogle Scholar
  • 20 Razvi S, Vaidya B, Perros P. et al. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves’ disease. Eur J Endocrinol 2006; 154: 783-786
    CrossrefPubMedGoogle Scholar
  • 21 Boelaert K, Edward Visser W, Taylor PN. et al. Endocrinology in the time of COVID-19: management of hyperthyroidism and hypothyroidism. Eur J Endocrinol 2020; 183: G33-G39
    CrossrefPubMedGoogle Scholar
  • 22 Francis N, Francis T, Lazarus JH. et al. Current controversies in the management of Graves’ hyperthyroidism. Expert Rev Endocrinol Metab 2020; 15: 159-169
    CrossrefPubMedGoogle Scholar
  • 23 Struja T, Fehlberg H, Kutz A. et al. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol 2017; 176: 87-97
    CrossrefPubMedGoogle Scholar
  • 24 Subekti I, Pramono LA. Current diagnosis and management of Graves’ disease. Acta Med Indones 2018; 50: 177-182
    PubMedGoogle Scholar
  • 25 Struja T, Kaeslin M, Boesiger F. et al. External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 2017; 176: 413-419
    CrossrefPubMedGoogle Scholar
  • 26 Effraimidis G. Predictive scores in autoimmune thyroid disease: are they useful?. Eur J Endocrinol 2019; 181: R119-R131
    CrossrefPubMedGoogle Scholar
  • 27 Jiang X, Hu H, Fu Z. et al. Association between the ctla-4 exon 1+49a/G polymorphism and the relapse of Grave’s disease after Atd withdrawal: a meta-analysis. Acta Endocrinol 2022; 18: 324-332
    PubMedGoogle Scholar
  • 28 Bartalena L, Burch HB, Burman KD. et al. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 2016; 84: 115-120
    CrossrefPubMedGoogle Scholar
  • 29 Sabini E, Mazzi B, Profilo MA. et al. High serum cholesterol is a novel risk factor for Graves’ orbitopathy: results of a cross-sectional study. Thyroid 2018; 28: 386-394
    CrossrefPubMedGoogle Scholar
  • 30 Lanzolla G, Sabini E, Profilo MA. et al. Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study. J Endocrinol Invest 2018; 41: 1417-1423
    CrossrefPubMedGoogle Scholar
  • 31 Lanzolla G, Vannucchi G, Ionni I. et al. Cholesterol serum levels and use of statins in Graves’ orbitopathy: a new starting point for the therapy. Front Endocrinol (Lausanne) 2020; 10: 1-8
    CrossrefPubMedGoogle Scholar